ELSEVIER

Drug and Alcohol Dependence 64 (2001) 371–374

DRUG and ALCOHOL DEPENDENCE

www.elsevier.com/locate/drugalcdep

Cumulative Author index

Volumes 61–64 (2001)

Aalto-Setälä, T. **62**, 175
Abraham, H.D. **63**, 277
Abrams, K. **64**, 219
Acosta, T. **63**, 69
Adelson, M. **61**, 191
Adler, M.W. **62**, 109
Alpan, G. **63**, 97
Alterman, A.I. **61**, 145, 271
Alterman, A.I. **62**, 19
Alterman, A.I. **63**, 69
Alvarez, A.I. **64**, 27
Alvarez, F.J. **64**, 19
Amass, L. **61**, 173
Andrzejewski, M.E. **63**, 179
Antelman, S.M. **61**, 3
Anthony, J.C. **63**, 245
Anthony, J.C. **64**, 123
Anttila, T. **62**, 175
Arfken, C.L. **61**, 287
Arsenault, J.R. **64**, 299
Ator, N.A. **61**, 55, 69
Avants, S.K. **61**, 35
Averill, P. **63**, 207

Babb, D.A. **63**, 131
Backmund, M. **64**, 173
Badger, G.J. **64**, 111
Balldin, J. **63**, 263
Balster, R.L. **61**, 1
Balster, R.L. **63**, 1
Barbanoj, M.J. **62**, 215
Barrau, K. **61**, 281
Barrio, G. **63**, 169
Batlle, F. **63**, 187
Battegay, M. **64**, 105
Bauer, G. **61**, 307
Bauer, G. **64**, 251
Bauer, L.O. **63**, 87
Baumann, P. **61**, 47
Bayer, B.M. **62**, 141
Bein, E. **61**, 105
Ben-Abdallah, A. **61**, 223
Berggren, U. **63**, 263
Bernal, S.A. **63**, 215
Bickel, W.K. **61**, 249
Bickel, W.K. **64**, 111
Bigelow, G.E. **64**, 271
Billaud, J.-N. **62**, 125
Billet, O. **62**, 125
Bleich, A. **61**, 191
Bluthenthal, R.N. **62**, 225
Booth, R.E. **64**, 165
Bourquin, M. **61**, 47
Bovasso, G.B. **62**, 19
Bravo, M.J. **63**, 169
Breiter, H. **61**, 163
Breslau, N. **64**, 1
Brower, K.J. **61**, 23
Brown, S. **63**, 131
Bucher, H.C. **64**, 105

Cabral de Oliveira, C. **64**, 27
Cacciola, J.S. **61**, 145, 271
Camí, J. **64**, 285
Canet, J. **63**, 117
Canino, G. **63**, 229
Carmen del Rio, M. **64**, 19
Carpenter, K.M. **63**, 51
Carpenter, M.J. **62**, 191
Carter, K.M. **64**, 299
Casas, M. **63**, 187
Cascio, A. **63**, 117
Celentano, D. **61**, 113
Celentano, D.D. **61**, 315
Celentano, D.D. **62**, 195
Celentano, D.D. **64**, 55
Chantarujikapong, S.I. **61**, 95
Chao, C.C. **62**, 149
Charuvastra, V.C. **63**, 139
Chung, S.-e. **64**, 55
Chutuape, M.A. **61**, 137
Chutuape, M.A. **62**, 69
Clark, D.B. **61**, 3
Clarke, J. **61**, 211
Cnaan, A. **63**, 69
Cohn, S. **61**, 315
Coiro, V. **61**, 217
Colón, H.M. **63**, 229
Compton, P. **63**, 139
Compton, W.M. **61**, 223
Cone, E.J. **63**, 97
Connor, J.P. **61**, 129
Coovert, M.D. **62**, 205
Copeland, A.L. **62**, 91
Cornish, J. **63**, 69
Cornish, J.W. **61**, 183
Cornish, J.W. **62**, 1
Cottler, L.B. **61**, 223
Coviello, D.M. **61**, 145
Craft, R.M. **63**, 215
Crosby, J. **64**, 203
Cross, J.C. **64**, 191
Cross, S.I. **61**, 113
Crowley, T.J. **61**, 237
Crum, R.M. **62**, 195

D'Ambra, M.N. **61**, 163
Darke, S. **62**, 77
Daunais, J.B. **61**, 15
Davies, H.M.L. **61**, 15
Davies, M. **64**, 233
Davis, W.R. **64**, 191
Dawes, M.A. **61**, 3
Degenhardt, L. **64**, 319
Déglon, J.-J. **61**, 47
Déglon, J.-J. **62**, 97
De La Fuente, L. **63**, 169
de la Torre, R. **64**, 285
Dhillon, A.S. **63**, 199
Di Marino, M.E. **64**, 35
Dixon, J. **64**, 337
Djezzar, S. **61**, 281
Dominguez, G. **62**, 157
Donahoe, R.M. **62**, 109, 131
Downey, K.K. **61**, 287
Dunn, J. **63**, 79
Duro, P. **63**, 187

Eap, C.B. **61**, 47
Ehrman, R.N. **61**, 183
Ehrman, R.N. **62**, 1
Eichenlaub, D. **64**, 173
Eisen, S.A. **61**, 95
Eisenstein, T.K. **62**, 111
Elman, I. **61**, 163
Eriksson, M. **63**, 263
Evans, S.M. **64**, 271

Faggiano, F. **64**, 329
Fahlke, C. **63**, 263
Farré, M. **64**, 285
Fendrich, M. **62**, 239
Ferrando, A. **64**, 27
Ferri, C.P. **63**, 79
Fischman, M.W. **64**, 271
Foltin, R.W. **64**, 63, 271
France, C.P. **63**, 39

Frederick-Osborne, S.L. **63**, 269
Freeman, W.M. **61**, 15
Friedmann, P.D. **64**, 47
Fudala, P.J. **61**, 183

Galen, L.W. **61**, 23
Galen, L.W. **62**, 205
Galloway, G.P. **63**, 269
García, L. **63**, 117
Gariti, P. **63**, 69
Gastfriend, D.R. **61**, 163
Gekker, G. **62**, 149
Gekker, G. **64**, 257
Gelkopf, M. **61**, 191
Geninatti, S. **64**, 329
Gerak, L.R. **63**, 39
Gerostamoulos, J. **61**, 123
Gerra, G. **64**, 63
Giancola, P. **61**, 3
Giedd, J.N. **62**, 49
Gillespie, B.W. **61**, 23
Gilman, S.E. **63**, 277
Gioia, L. **61**, 15
Gitchell, J.G. **64**, 35
Glantz, M.D. **62**, 57
Glautier, S. **64**, 337
Glennon, R.A. **64**, 203
Glowa, J.R. **62**, 41
Gmel, G. **64**, 151
Gogineni, A. **62**, 225
Gogineni, A. **64**, 47
Goldberg, J. **61**, 95
Golden, A.S. **63**, 97
Gorgerat, S. **64**, 203
Gossop, M. **62**, 255
Goto, K. **64**, 133
Gottschalk, C. **62**, 49
Gough, R. **64**, 203
Grabowski, J. **63**, 207
Greenwood, G.L. **61**, 105
Griffiths, P. **64**, 9
Griffiths, R.R. **61**, 69
Gross, A. **64**, 111
Grupp, L. **61**, 35
Gupman, A.E. **61**, 261
Gupman, A.E. **62**, 57
Gyr, N. **64**, 105

Hall, S.K. **61**, 237
Hall, W. **62**, 163
Hall, W. **63**, 147
Hall, W. **64**, 319
Hameedi, F. **63**, 155
Haney, M. **64**, 63
Harris, D.S. **61**, 85
Harris, L.S. **63**, 39
Hart, S.L. **61**, 15
Hartz, D.T. **63**, 269
Hasin, D.S. **63**, 51
Hatsukami, D.K. **63**, 131
Hatzimanolis, J. **64**, 363
Haug, N. **61**, 297
Haug, N.A. **63**, 97
Hayward, R. **61**, 191
H. Drummer, O. **61**, 123
Heeb, J.-L. **64**, 151
Hein, N.D. **64**, 299
Helmus, T.C. **61**, 287
Henderson, M.J. **61**, 287
Henderson, M.J. **62**, 205
Hernández, C. **64**, 285
Höfler, M. **64**, 347
Holtzman, S.G. **62**, 83
Hönigschnabl, S. **61**, 307
Hönigschnabl, S. **64**, 251
Hoover, D.R. **64**, 55
Howard, M.O. **61**, 223
Huang, F.-Y. **64**, 233
Hudson, A.L. **64**, 203
Huggins, G.R. **63**, 97
Hughes, J.R. **62**, 191
Hung, Y.-Y. **64**, 181
Hunkeler, E.M. **64**, 181
Hu, S. **62**, 149
Husbands, S.M. **64**, 203
Hu, T.-w. **64**, 181

Iguchi, M.Y. **63**, 179
Ikemoto, S. **64**, 133
Ippolito, R. **64**, 329
Ishiguro, T. **64**, 133

Jacobs, E.A. **64**, 111
Jacobsen, L.K. **62**, 49
Jansson, L.M. **63**, 97
Jasinski, D.R. **63**, 97
John, D. **64**, 165
Johnson, B.D. **64**, 191
Johnson, E.O. **61**, 261
Johnson, E.O. **64**, 1
Johnson, R.E. **63**, 97
Jones, H.E. **61**, 297
Jones, H.E. **63**, 97
Jones, R.T. **61**, 85
Joyce, A. **62**, 157
Juday, T. **61**, 195

Kaff, A. **64**, 251
Kaff, G. **61**, 307
Kamali, F. **64**, 265
Kamien, J.B. **61**, 173
Kaminski, B.J. **61**, 69
Kampman, K.M. **63**, 69
Kandel, D.B. **64**, 233
Kane, M. **61**, 163
Katz, E.C. **61**, 137
Kautz, M.A. **61**, 69
Kaye, S. **62**, 77
Ketelsen, D. **62**, 131
Kirby, K.C. **63**, 179
Kissin, W.B. **63**, 97
Kleber, H.D. **61**, 195
Knowlton, A.R. **64**, 55
Koppenhaver, J.M. **62**, 19
Kopstein, A.N. **62**, 195
Kosten, T. **63**, 253
Kosten, T.R. **62**, 49
Kosten, T.R. **63**, 155
Krause, S. **61**, 163
Kreek, M.J. **62**, 49
Kuhar, M.J. **62**, 157
Kushner, M. **64**, 219
Kwiatkowski, C.F. **64**, 165

Labouvie, E. **62**, 231
Ladewig, D. **62**, 97
Ladewig, D. **64**, 105
Lagier, G. **61**, 281
Lambert, H. **61**, 281
Lantz, M.E. **63**, 97
Laranjeira, R. **62**, 231
Laranjeira, R. **63**, 79
László, L. **61**, 155
Latkin, C.A. **64**, 55, 97
Le Sage, M.G. **62**, 41
Lester, B.M. **63**, 97
Levin, F.R. **64**, 271
Lew, C. **63**, 169
Lewis, J.W. **64**, 203
Liberty, H.J. **64**, 191
Lichtman, A.H. **63**, 107
Lieb, R. **64**, 347
Liguori, A. **63**, 123
Lin, E. **61**, 85
Ling, W. **63**, 139
Lisdahl Medina, K. **64**, 219
Livoti, S. **61**, 47
Livoti, S. **62**, 97
Lokensgard, J.R. **64**, 257
Longshore, D. **62**, 225
Lönnqvist, J. **62**, 175
Luce, D. **63**, 69
Lukas, S.E. **64**, 143
Lykouras, L. **64**, 363
Lyles, C.M. **61**, 113
Lynch, K.G. **64**, 75
Lynskey, M. **64**, 319
Lyons, M.J. **61**, 95

Maany, I. **61**, 183
Macenski, M.J. **64**, 243
Madden, J.J. **62**, 131
Maksad, J. **61**, 211
Mantle, D. **63**, 199
Margolin, A. **61**, 35
Markianos, M. **64**, 363
Mark, T.L. **61**, 195
Márquez, M. **63**, 117
Marsden, J. **62**, 255
Martin, B.R. **63**, 107
Martin, J.-L. **61**, 47
Martin, S.S. **62**, 195
Marttunen, M. **62**, 175

Mas, M. **64**, 285
McCance-Katz, F.E. **63**, 155
McCarthy, L. **62**, 111
McCaul, M.E. **62**, 9
McKay, J.R. **61**, 145, 271
McKay, J.R. **62**, 19
Mellon, R.D. **62**, 141
Mendelson, J. **61**, 85
Menoyo, E. **64**, 285
Meyer, K. **64**, 173
Mezzich, A. **61**, 3
Micallef, J. **61**, 281
Mikulich, S.K. **61**, 173, 237
Miles, D.R. **61**, 261
Miles, D.R. **62**, 57
Mitola, B. **64**, 329
Moeller, F.G. **63**, 207
Moore, R.D. **62**, 9
Morral, A.R. **63**, 179
Morris, R. **61**, 163
Moss, H.B. **64**, 75
Moussas, G. **64**, 363
Muller, E. **63**, 69
Müller, F. **61**, 155
Mulvaney, F. **63**, 69
Mulvaney, F.D. **61**, 271
Mulvaney, F.D. **62**, 19
Muñoz, A. **61**, 315
Murray, K.S. **64**, 309

Nader, M.A. **63**, 39
Naef, M.R. **64**, 105
Nagy, J. **61**, 155
Nelson, K.E. **61**, 113
Newbury-Birch, D. **64**, 265
Newlin, D.B. **61**, 261
Newlin, D.B. **62**, 57
Nicholson, K.L. **63**, 1
Nishijima, K. **64**, 133
Nutt, D.J. **64**, 203

O'Brien, C. **63**, 69
O'Brien, C.P. **61**, 183
O'Brien, J. **64**, 337
Ogden, B.A. **64**, 299
Oliveto, A. **63**, 155
Orozco, S. **64**, 143
Ortiz, M. **63**, 117
Osmond, D.H. **61**, 105

Page-Shafer, K. **61**, 105
Paice, A. **63**, 199
Palmer, T.N. **63**, 199
Pandina, R. **62**, 231
Patrick, G.A. **63**, 39
Paty, J.A. **64**, 35
Paul, J. **61**, 105
Pérez de los Cobos, J. **63**, 187
Peterson, P.K. **62**, 149
Peterson, P.K. **64**, 257
Peters, T.J. **63**, 199
Petitjean, S. **62**, 97
Petrakis, I. **63**, 155
Petry, N.M. **62**, 31
Petry, N.M. **63**, 29
Petry, N.M. **64**, 111
Pfister, H. **64**, 347
Pfudl, S. **64**, 251
Phillips, T.R. **62**, 125
Pickens, R.W. **61**, 261
Pickens, R.W. **62**, 57
Pilowsky, D.J. **61**, 113
Pinsky, I. **62**, 231
Poikolainen, K. **62**, 175
Poklis, A. **63**, 107
Poklis, J.L. **63**, 107
Poole, S. **63**, 69
Porrino, L.J. **61**, 15
Powell, K. **61**, 47
Powell, K.R. **62**, 83
Preedy, V.R. **63**, 199
Preston, K.L. **61**, 261
Price, R.K. **64**, 309
Prieto, J.G. **64**, 27

Ranaldi, R. **64**, 209
Rehm, J. **64**, 151
Rhoades, H.M. **63**, 207
Riba, J. **62**, 215
Ribalta, E. **63**, 187
Ricciardelli, L.A. **61**, 129
Rice, D.P. **64**, 181
Rice, K.C. **62**, 41
Riggs, R.L. **62**, 191
Rinder, H.M. **61**, 35
Risk, N.K. **64**, 309
Risser, D. **61**, 307
Risser, D. **64**, 251
Robbins, S.J. **61**, 183
Robbins, S.J. **62**, 1
Robinson, J.H. **63**, 123
Rodríguez-Fornells, A. **62**, 215
Rogers, T.J. **62**, 111
Rohay, J.M. **64**, 35
Rosenberg, M.F. **63**, 245
Rosenberg, M.F. **64**, 123
Rosenheck, R. **63**, 253
Roset, P.N. **64**, 285
Ross, J. **62**, 77
Rowlett, J.K. **61**, 229
Royuela, L. **63**, 169
Rutherford, M.J. **61**, 145, 271

Sanmarco, J.L. **61**, 281
Scherrer, J.F. **61**, 95
Schmitz, J.M. **63**, 207
Schneider, B. **61**, 307
Schuster, C.R. **61**, 287
Schütz, C.G. **64**, 173
Sebald, D. **61**, 307
Sebald, D. **64**, 251
Seguí, J. **63**, 117
Setaro, J.F. **61**, 35
Shelton, K.L. **64**, 243
Sheng, W.S. **62**, 149
Sherman, S.G. **64**, 97
Shiffman, S. **64**, 35
Siliquini, R. **64**, 329
Silverman, K. **61**, 297
Silverman, K. **62**, 69
Singha, A. **63**, 155
Sliker, J.K. **62**, 111
Smith, B.J. **61**, 249
Sobota, M. **64**, 117
Sofuoglu, M. **63**, 131
Soine, W.H. **64**, 299
Sonntag, H. **64**, 347
Sorensen, J.L. **62**, 91
Soriano, J. **61**, 261
Spagnoli, J. **61**, 47
Spitznagel, E.L. **64**, 309
Stafford, D. **62**, 41
Staikos, V. **61**, 123
Stall, R.D. **61**, 105
Stein, M. **62**, 225
Stein, M.D. **61**, 211
Stein, M.D. **64**, 47, 117
Stewart, D. **62**, 255
Stewart, D. **64**, 9
Stichenwirth, M. **61**, 307
Stichenwirth, M. **64**, 251
Stitzer, M. **61**, 297
Stitzer, M.L. **61**, 137
Stitzer, M.L. **62**, 69
Stohler, R. **62**, 97
Stotts, A.L. **63**, 207
Strassman, R.J. **62**, 215
Susman, E.J. **61**, 3
Svikis, D. **61**, 297
Svikis, D.S. **62**, 9
Svikis, D.S. **63**, 97
Swift, W. **63**, 147

Tarter, R.E. **61**, 3
Teesson, M. **63**, 147
Tejero, A. **63**, 187
Thirion, X. **61**, 281
Torrens, M. **63**, 169
Treacy, S. **62**, 255
True, W.R. **61**, 95
Trujols, J. **63**, 187
Tsuang, M. **61**, 95
Tuffy, L. **61**, 163
Tuulio-Henriksson, A. **62**, 175
Tyacke, R. **64**, 203

Uehlinger, C. **62**, 97
Umbricht, A. **61**, 261
Upton, R.A. **61**, 85

van den Bree, M.B.M. **61**, 261
van den Bree, M.B.M. **62**, 57
Vanyukov, M.M. **61**, 3

Varner, K.J. **64**, 299
Versino, E. **64**, 329
Vescovi, P.P. **61**, 217
Vila, L. **64**, 27
Virgo, K.S. **64**, 309
Vlahov, D. **61**, 113, 315
Vlahov, D. **64**, 55
Voces, J. **64**, 27
Voight, A. **64**, 219
Volpicelli, J.R. **63**, 69
von Sydow, K. **64**, 347
Vrana, K.E. **61**, 15
Vycudilik, W. **61**, 307

Waldvogel, D. **62**, 97
Walker, D.J. **64**, 85
Walshaw, D. **64**, 265
Walsh, S.L. **64**, 271
Wang, Z. **64**, 209
Ward, A.S. **64**, 63
Ward, K. **62**, 19
Warner, L.A. **63**, 229
Weerts, E.M. **61**, 69
Weisner, C. **64**, 181
Welm, S. **61**, 85
Wetzel, M. **62**, 111
Whaley, W.L. **62**, 131
White, E.W. **61**, 105
Whitmore, E.A. **61**, 237
Wilkins, D.G. **63**, 97
Williams, R.J. **61**, 129
Wilson, D.M. **63**, 107
Winger, G. **62**, 181
Winger, G. **63**, 39
Winstock, A.R. **64**, 9
Wittchen, H.-U. **64**, 347
Woods, J.H. **62**, 181
Woods, J.H. **63**, 39
Woody, G.E. **61**, 195
Woolverton, W.L. **61**, 229
Woolverton, W.L. **63**, 39
Woolverton, W.L. **64**, 209

Xian, H. **61**, 95

Yohrling, G.J., IV **61**, 15
Yoshino, T. **64**, 133
Young, R.M.D. **61**, 129
Yui, K. **64**, 133
Yun Soo Kim, J. **62**, 239

Zacny, J.P. **63**, 23
Zacny, J.P. **64**, 85
Zanis, D.A. **61**, 145
Zinkernagel, C. **64**, 105
Zucker, R.A. **61**, 23

ELSEVIER

Drug and Alcohol Dependence 64 (2001) 375–389

DRUG and ALCOHOL DEPENDENCE

www.elsevier.com/locate/drugalcdep

Cumulative Subject index

Volumes 61–64 (2001)

Absorption rate; Flunitrazepam; Pharmacokinetics; Rate of onset of effects; Abuse liability **64**, 285

Abuse; Buprenorphine; Buprenorphine-naloxone; Dosing regimen; Pharmacotherapy **61**, 173

Abuse; Cannabis; Cohort; Dependence; Gender; Longitudinal study; Use **64**, 347

Abuse liability; Flunitrazepam; Absorption rate; Pharmacokinetics; Rate of onset of effects **64**, 285

Abuse liability; Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Inhalants; Human **64**, 85

Abuse potential; Benzodiazepine; Barbiturates; Pentobarbital; Drug discrimination; Panadiplon (U-78875, PNU-78875) **61**, 229

Abuse potential; Benzodiazepine; CL 284846; Dependence; Feeding; Triazolam; Zaleplon **61**, 69

Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Abuse potential; Cocaine; GBR 12909; Phentermine; Progressive ratio; Self-administration; Pharmacotherapy **62**, 41

Academic achievement; Adolescence; Cannabis; Coitus; Lack of interest **62**, 175

Accidents; Cannabis; Respiratory disease; Dependence; Adverse effects **62**, 163

ACE-inhibitors; Cocaine; Cardiovascular; Platelet activation; Methadone; Fosinopril **61**, 35

Acetaldehyde; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

ACTH; Anesthesia; Naltrexone; Cortisol; Craving; Withdrawal **61**, 163

Add health study; Genetic and environmental influences; Marijuana use; Sensation seeking; Risk taking **62**, 57

Addiction; Methadone; Enantiomer; Blood; Cytochrome P-450 **61**, 47

Administration route; Heroin; Dependence; SDS scale **63**, 169

Adolescence; Academic achievement; Cannabis; Coitus; Lack of interest **62**, 175

Adolescence; Alcohol; Culture; Dependence; Epidemiology **63**, 229

Adolescence; Liability; Puberty; Affective, cognitive, and behavioral dysregulation; Neuroadaptation; Substance use disorder **61**, 3

Adolescents; Alcohol use disorders; Disruptive behaviors **64**, 75

Adolescent; Sleep problems; Insomnia; Alcohol; Tobacco; Drug abuse **64**, 1

Adolescents; Sensation seeking; Cigarette use; Disinhibition; Marijuana use **62**, 195

Adverse effects; Cannabis; Accidents; Respiratory disease; Dependence **62**, 163

Affective, cognitive, and behavioral dysregulation; Liability; Puberty; Adolescence; Neuroadaptation; Substance use disorder **61**, 3

Age; Sequence of substance use; Drug users; Opiates; Heroin **64**, 105

Aggression; Epidemiology; Delinquent behavior; Conduct disorder; Substance-related disorders **63**, 245

Alcohol abuse; Drinking and driving; Alcohol consumption; Traffic accidents; Social problems **62**, 231

Alcohol abuse; Polydrug abuse; Behavioral economics **62**, 31

Alcohol; Adolescence; Culture; Dependence; Epidemiology **63**, 229

Alcohol; Adolescent; Sleep problems; Insomnia; Tobacco; Drug abuse **64**, 1

Alcohol; Caffeine; Automobile driving; Equilibrium; Psychomotor performance **63**, 123

Alcohol; Cannabis; Comorbidity; Drug use; Population; Tobacco **64**, 319

Alcohol challenge; Social phobia; Co-morbidity; Alcohol use; Laboratory stress **64**, 219

Alcohol consumption; Drinking and driving; Alcohol abuse; Traffic accidents; Social problems **62**, 231

Alcohol dependence; Alcohol withdrawal; NMDA receptor; Excitotoxicity; Primary cortical culture **61**, 155

Alcohol dependence; Genetic; Illicit drug dependence; Posttraumatic stress disorder; Twins; Veterans **61**, 95

Alcohol dependence; Panic disorder; Cultural factors; Major depression; Dysthymia **63**, 117

Alcohol detoxification; Dopamine receptor responsivity; Relapse prediction **64**, 363

Alcohol expectancies; Alcohol motives **62**, 205

Alcoholic subtype; Cluster analysis; DSM-IV alcohol dependence; Type I/II–Type A/B **63**, 51

Alcoholism; Depressive disorder; Comorbidity; Epidemiology **63**, 277

Alcoholism; Gamma-amino-butyric acid; Gamma-hydroxy-butyric acid; Growth hormone **61**, 217

Alcohol; Medical students; Pre-registration house officers; Illicit drugs; Stress **64**, 265

Alcohol motives; Alcohol expectancies **62**, 205

Alcohol; Negative reinforcement; Heavy drinkers **64**, 337

Alcohol; Prolactin; Fenfluramine; SSRI **63**, 263

Alcohol use disorders; Adolescents; Disruptive behaviors **64**, 75

Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Psychometric analysis; Switzerland; Confirmatory factor analysis **64**, 151

Alcohol use; HMO alcohol costs; Drinking patterns and costs; U-shaped drinking curve **64**, 181

Alcohol use; Social phobia; Co-morbidity; Alcohol challenge; Laboratory stress **64**, 219

Alcohol withdrawal; Alcohol dependence; NMDA receptor; Excitotoxicity; Primary cortical culture **61**, 155

Alprazolam; Caffeine; Drug discrimination; Humans; Novel-response procedure; Triazolam; Zolpidem **61**, 249

Amantadine; Cocaine use disorder; Detoxification; Heroin dependence; Methadone; Opioid withdrawal **63**, 187

Analgesia; Marijuana smoking; Cannabinoid; Δ^9-THC; SR 141716A; Antinociception; Catalepsy; Hypothermia **63**, 107

Analgesia; κ-Opioids; Locomotor activity; Gender **63**, 215

Anesthesia; Naltrexone; ACTH; Cortisol; Craving; Withdrawal **61**, 163

Antinociception; Marijuana smoking; Cannabinoid; Δ^9-THC; SR 141716A; Analgesia; Catalepsy; Hypothermia **63**, 107

Anti-social personality disorder; Novelty seeking; Buprenorphine; Heroin dependence; Poly-drug use; Contingency management; Treatment outcome **61**, 287

Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Evoked potentials; Conduct disorder; EEG **63**, 87

Antisocial; Treatment outcome; Substance abuse; Gender; Outpatient **61**, 23

Assessment; Cocaine; Follow-up; Treatment **62**, 19

Attendance; Outpatient treatment; Substance use diagnosis; Gender; Ethnicity; Employment status **62**, 9

Australian adults; DSM-IV; ICD-10; Cannabis dependence **63**, 147

Automobile driving; Alcohol; Caffeine; Equilibrium; Psychomotor performance **63**, 123

Automobile driving licence; Illegal drugs; Fitness to drive; Drug-Dependence **64**, 19

Autonomic nervous system; Immunobiology; Opiates; Nicotinic receptor; Lympbocytes **62**, 141

Barbiturates; Benzodiazepine; Pentobarbital; Drug discrimination; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229

Behavioral economics; Polydrug abuse; Alcohol abuse **62**, 31

Behavioral incentives; Pregnancy; Contingency management; Perinatal addictions; Methadone maintenance **61**, 297

Behavioral treatment; Smoking cessation; Self-help; Nicotine replacement; Smoking **64**, 35

Behavior; Opioid; Morphine; Sex; Gender; Human **63**, 23

Benzodiazepine; Abuse potential; CL 284846; Dependence; Feeding; Triazolam; Zaleplon **61**, 69

Benzodiazepine; Barbiturates; Pentobarbital; Drug discrimination; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229

Beta-blocker; Cocaine withdrawal; Propranolol; Pharmacotherapy; Double-blind **63**, 69

Biochemical mechanisms; Myopathy; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

Blind dosing; Methadone maintenance; Drug dependence; Clinic policy; Patient-therapist relationship; Candor; Medical ethics **61**, 191

Blood; Methadone; Enantiomer; Addiction; Cytochrome P-450 **61**, 47

Blood pressure; Ephedrine; Heart rate; Illicit synthesis; Pseudoephedrine; Rat **64**, 299

Brain imaging; Hormonal effects; Magnetic resonance imaging; Cocaine dependence **62**, 49

Brazil; Substance misuse; Cocaine; Epidemiological methods; Sampling **63**, 79

Buprenorphine; Buprenorphine-naloxone; Dosing regimen; Abuse; Pharmacotherapy **61**, 173

Buprenorphine; Heroin dependence; Human; Opioid withdrawal; Treatment **64**, 111

Buprenorphine-naloxone; Buprenorphine; Dosing regimen; Abuse; Pharmacotherapy **61**, 173

Buprenorphine; Naloxone; Opiate withdrawal; Sublingual; Pharmacokinetics **61**, 85

Buprenorphine; Novelty seeking; Anti-social personality disorder; Heroin dependence; Poly-drug use; Contingency management; Treatment outcome **61**, 287

Buprenorphine; Opiate addiction; Methadone maintenance; Cost-effectiveness **63**, 253

Buprenorphine; Pain; Methadone; Cold pressor; Hyperalgesia **63**, 139

Buprenorphine; Pregnancy; Opioid dependence; Treatment; Neonatal abstinence syndrome; Perinatal addiction **63**, 97

Buprenorphine tablet; Methadone maintenance; Opioids; Controlled trial **62**, 97

Bupropion; Cocaine; Pharmacotherapy **63**, 155

Caffeine; Alcohol; Automobile driving; Equilibrium; Psychomotor performance **63**, 123

Caffeine; Alprazolam; Drug discrimination; Humans; Novel-response procedure; Triazolam; Zolpidem **61**, 249

Candor; Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Patient-therapist relationship; Medical ethics **61**, 191

Cannabinoid; Marijuana smoking; Δ^9-THC; SR 141716A; Antinociception; Analgesia; Catalepsy; Hypothermia **63**, 107

Cannabis; Abuse; Cohort; Dependence; Gender; Longitudinal study; Use **64**, 347

Cannabis; Academic achievement; Adolescence; Coitus; Lack of interest **62**, 175

Cannabis; Accidents; Respiratory disease; Dependence; Adverse effects **62**, 163

Cannabis; Comorbidity; Drug use; Population; Alcohol; Tobacco **64**, 319

Cannabis dependence; DSM-IV; ICD-10; Australian adults **63**, 147

Cannabis; Substance-related disorders; Epidemiologic studies; Survival analysis; Natural history **64**, 123

Capillarity; Ethanol; Exercise; Muscle metabolism; Fiber area; Fiber type; Rats **64**, 27

β-carbolines; Harmine; Harmaline; Hallucinogens; Imidazoline binding sites; SAR **64**, 203

Cardiovascular; Cocaine; Platelet activation; Methadone; ACE-inhibitors; Fosinopril **61**, 35

Cardiovascular effects; Cocaine; Pharmacotherapy; Flupenthixol; Subjective effects; Pharmacokinetic effects **64**, 271

CART; Drug abuse; Genes; Gene expression **62**, 157

Case management; HIV/AIDS; Health service utilization; Drug treatment; Injection drug users **64**, 55

Catalepsy; Marijuana smoking; Cannabinoid; Δ^9-THC; SR 141716A; Antinociception; Analgesia; Hypothermia **63**, 107

Catecholamines; Tyrosine hydroxylase; Cocaine; Mesolimbic pathway; Tropanes **61**, 15

Cats; Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Opiates; Molecular biology **62**, 125

Children; Injection drug users; HIV; Parental drug use; Children of substance abusing parents; Foster care **61**, 113

Children of substance abusing parents; Injection drug users; Children; HIV; Parental drug use; Foster care **61**, 113

Choice; Nitrous oxide; Subjective effects; Reinforcing effects; Abuse liability; Inhalants; Human **64**, 85

CIDI-SAM; Substance abuse and dependence; Diagnosis; Physiological dependence; Nosology **61**, 237

Cigarette use; Sensation seeking; Adolescents; Disinhibition; Marijuana use **62**, 195

CL 284846; Abuse potential; Benzodiazepine; Dependence; Feeding; Triazolam; Zaleplon **61**, 69

CL 284,846; Abuse potential; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Clinic policy; Methadone maintenance; Blind dosing; Drug dependence; Patient-therapist relationship; Candor; Medical ethics **61**, 191

Cluster analysis; Alcoholic subtype; DSM-IV alcohol dependence; Type I/II–Type A/B **63**, 51

Cocaine; Assessment; Follow-up; Treatment **62**, 19

Cocaine; Bupropion; Pharmacotherapy **63**, 155

Cocaine; Cardiovascular; Platelet activation; Methadone; ACE-inhibitors; Fosinopril **61**, 35

Cocaine; D2 agonists; Psychomotor stimulant; Self-administration; Positive reinforcement; Rhesus monkey **64**, 209

Cocaine dependence; Antisocial personality disorder; Time perception; Contingent negative variation; Evoked potentials; Conduct disorder; EEG **63**, 87

Cocaine dependence; Brain imaging; Hormonal effects; Magnetic resonance imaging **62**, 49

Cocaine dependence; Cocaine use; Urine test; Treatment outcome **62**, 1

Cocaine dependence; Pharmacotherapy; Ritanserin; Serotonin antagonist; Treament **61**, 183

Cocaine dependence; Treatment intensity; Psychosocial treatment; Outpatient; Day hospital; Services **61**, 145

Cocaine; Depressive symptoms; Depression; Physiological response; Subjective response **63**, 131

Cocaine; Fluoxetine; Depression; Dual-diagnosis; Treatment **63**, 207

Cocaine; GBR 12909; Phentermine; Progressive ratio; Self-administration; Pharmacotherapy; Abuse potential **62**, 41

Cocaine; Longitudinal; Marijuana; Methodology; Survey **62**, 239

Cocaine; Methadone; Take-homes; Contingency management; Opiates **62**, 69

Cocaine; Methamphetamine; Stimulant; Treatment; HIV **62**, 91

Cocaine; Pharmacotherapy; Flupenthixol; Subjective effects; Cardiovascular effects; Pharmacokinetic effects **64**, 271

Cocaine powder; Crack; Heroin; Economics; Employment; Gender; Epidemiology **64**, 191

Cocaine; Substance misuse; Epidemiological methods; Sampling; Brazil **63**, 79

Cocaine; Tyrosine hydroxylase; Catecholamines; Mesolimbic pathway; Tropanes **61**, 15

Cocaine use; Cocaine dependence; Urine test; Treatment outcome **62**, 1

Cocaine use disorder; Amantadine; Detoxification; Heroin dependence; Methadone; Opioid withdrawal **63**, 187

Cocaine withdrawal; Prolactin; Cortisol; Serotonin; Dopamine **64**, 63

Cocaine withdrawal; Propranolol; Pharmacotherapy; Double-blind; Beta-blocker **63**, 69

Codeine; Opioid addiction; Detoxification; Heroin; Methadone **64**, 173

Cognitions; Drinking; Gender differences; Response conflict; Gender stereotypes **61**, 129

Cohort; Abuse; Cannabis; Dependence; Gender; Longitudinal study; Use **64**, 347

Coitus; Academic achievement; Adolescence; Cannabis; Lack of interest **62**, 175

Cold pressor; Pain; Methadone; Buprenorphine; Hyperalgesia **63**, 139

Comorbidity; Alcoholism; Depressive disorder; Epidemiology **63**, 277

Comorbidity; Cannabis; Drug use; Population; Alcohol; Tobacco **64**, 319

Comorbidity; Methadone; Treatment outcome; Personality disorders; Psychiatric diagnosis **61**, 271

Co-morbidity; Social phobia; Alcohol use; Alcohol challenge; Laboratory stress **64**, 219

Complications; Intravenous drug use; Utilization; Services research **64**, 117

Conduct disorder; Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Evoked potentials; EEG **63**, 87

Conduct disorder; Epidemiology; Aggression; Delinquent behavior; Substance-related disorders **63**, 245

Confirmatory factor analysis; Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Psychometric analysis; Switzerland **64**, 151

Contingency management; Methadone; Take-homes; Opiates; Cocaine **62**, 69

Contingency management; Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Poly-drug use; Treatment outcome **61**, 287

Contingency management; Pregnancy; Behavioral incentives; Perinatal addictions; Methadone maintenance **61**, 297

Contingency management; Substance dependence; Inpatient detoxification; Outpatient aftercare; Treatment compliance **61**, 137

Contingency management; Technology transfer; Performance feedback; Incentives; Performance management; Drug treatment counselors **63**, 179

Contingent negative variation; Antisocial personality disorder; Time perception; Cocaine dependence; Evoked potentials; Conduct disorder; EEG **63**, 87

Controlled trial; Buprenorphine tablet; Methadone maintenance; Opioids **62**, 97

Convergent analysis; Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Subjective effects; Reliability **62**, 215

Correlates; Gay and Bisexual Men; Young; Substance Use; Prevalence **61**, 105

Cortisol; Anesthesia; Naltrexone; ACTH; Craving; Withdrawal **61**, 163

Cortisol; Cocaine withdrawal; Prolactin; Serotonin; Dopamine **64**, 63

Cost-effectiveness; Opiate addiction; Methadone maintenance; Buprenorphine **63**, 253

Cost-of-illness; Heroin; Opiates; Injecting drug use; Methadone; Economics; Policy **61**, 195

Crack; Cocaine powder; Heroin; Economics; Employment; Gender; Epidemiology **64**, 191

Craving; Anesthesia; Naltrexone; ACTH; Cortisol; Withdrawal **61**, 163

Craving; Methamphetamine; Relapse; Treatment **63**, 269

Cultural factors; Alcohol dependence; Panic disorder; Major depression; Dysthymia **63**, 117

Culture; Adolescence; Alcohol; Dependence; Epidemiology **63**, 229

Cytochrome P-450; Methadone; Enantiomer; Blood; Addiction **61**, 47

D2 agonists; Psychomotor stimulant; Cocaine; Self-administration; Positive reinforcement; Rhesus monkey **64**, 209

Dance drugs; Ecstasy; Dose related neurotoxicity; Polysubstance use; Harm reduction **64**, 9

Day hospital; Cocaine dependence; Treatment intensity; Psychosocial treatment; Outpatient; Services **61**, 145

Death; Toxicology; Heroin; Morphine; Demographics **61**, 123

Delinquent behavior; Epidemiology; Aggression; Conduct disorder; Substance-related disorders **63**, 245

Demographics; Toxicology; Heroin; Morphine; Death **61**, 123

Dependence; Abuse; Cannabis; Cohort; Gender; Longitudinal study; Use **64**, 347

Dependence; Abuse potential; Benzodiazepine; CL 284846; Feeding; Triazolam; Zaleplon **61**, 69

Dependence; Adolescence; Alcohol; Culture; Epidemiology **63**, 229

Dependence; Cannabis; Accidents; Respiratory disease; Adverse effects **62**, 163

Dependence; Heroin; Administration route; SDS scale **63**, 169

Depression; Depressive symptoms; Cocaine; Physiological response; Subjective response **63**, 131

Depression; Fluoxetine; Cocaine; Dual-diagnosis; Treatment **63**, 207

Depressive disorder; Alcoholism; Comorbidity; Epidemiology **63**, 277

Depressive symptoms; Depression; Cocaine; Physiological response; Subjective response **63**, 131

Detoxification; Amantadine; Cocaine use disorder; Heroin dependence; Methadone; Opioid withdrawal **63**, 187

Detoxification; Opioid addiction; Heroin; Methadone; Codeine **64**, 173

Diagnosis; Substance abuse and dependence; CIDI-SAM; Physiological dependence; Nosology **61**, 237

Diagnostic concordance; Inhalants; Volatile solvents; Nosology **61**, 223

Discrimination; Ethanol; Self-administration; Oral **64**, 243

Disinhibition; Sensation seeking; Adolescents; Cigarette use; Marijuana use **62**, 195

Disruptive behaviors; Adolescents; Alcohol use disorders **64**, 75

Distressing situations; Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; Noradrenergic hyperactivity; 3-Methoxytyramine **64**, 133

Dopamine; Cocaine withdrawal; Prolactin; Cortisol; Serotonin **64**, 63

Dopamine receptor responsivity; Alcohol detoxification; Relapse prediction **64**, 363

Dose related neurotoxicity; Ecstasy; Dance drugs; Polysubstance use; Harm reduction **64**, 9

Dosing regimen; Buprenorphine; Buprenorphine-naloxone; Abuse; Pharmacotherapy **61**, 173

Double-blind; Cocaine withdrawal; Propranolol; Pharmacotherapy; Beta-blocker **63**, 69

Drinking and driving; Alcohol abuse; Alcohol consumption; Traffic accidents; Social problems **62**, 231

Drinking; Gender differences; Response conflict; Cognitions; Gender stereotypes **61**, 129

Drinking patterns and costs; Alcohol use; HMO alcohol costs; U-shaped drinking curve **64**, 181

Drug abuse; Adolescent; Sleep problems; Insomnia; Alcohol; Tobacco **64**, 1

Drug abuse; Genes; Gene expression; CART **62**, 157

Drug-Dependence; Illegal drugs; Automobile driving licence; Fitness to drive **64**, 19

Drug dependence; Methadone maintenance; Blind dosing; Clinic policy; Patient-therapist relationship; Candor; Medical ethics **61**, 191

Drug discrimination; Abuse potential; CL 284,846; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Drug discrimination; Alprazolam; Caffeine; Humans; Novel-response procedure; Triazolam; Zolpidem **61**, 249

Drug discrimination; Benzodiazepine; Barbiturates; Pentobarbital; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229

Drug discrimination; Flunitrazepam; Self-administration; Rhesus monkey; Pentobarbital-dependent rats **63**, 39

Drug-related deaths; Forensic science; Forensic medicine; Emergency medicine; Drug-related emergencies **61**, 307

Drug-related emergencies; Forensic science; Forensic medicine; Emergency medicine; Drug-related deaths **61**, 307

Drug treatment counselors; Contingency management; Technology transfer; Performance feedback; Incentives; Performance management **63**, 179

Drug treatment; HIV/AIDS; Health service utilization; Case management; Injection drug users **64**, 55

Drug use; Cannabis; Comorbidity; Population; Alcohol; Tobacco **64**, 319

Drug use; Methadone; Maintenance; Emergency; Mortality **64**, 251

Drug users; Age; Sequence of substance use; Opiates; Heroin **64**, 105

Drug users; Injection sites; Sydney; Health **62**, 77

Drug users; Sexual risk behaviors; Sex partners; HIV **64**, 97

DSM-IV alcohol dependence; Alcoholic subtype; Cluster analysis; Type I/II–Type A/B **63**, 51

DSM-IV; ICD-10; Cannabis dependence; Australian adults **63**, 147

Dual-diagnosis; Fluoxetine; Cocaine; Depression; Treatment **63**, 207

Dysthymia; Alcohol dependence; Panic disorder; Cultural factors; Major depression **63**, 117

Early predictors; Opiate abuse; Mortality; Vietnam veterans; Follow-up **64**, 309

Economics; Crack; Cocaine powder; Heroin; Employment; Gender; Epidemiology **64**, 191

Economics; Heroin; Opiates; Injecting drug use; Methadone; Cost-of-illness; Policy **61**, 195

Ecstasy consumption; Prevalence; Social class; 18 year-olds **64**, 329

Ecstasy; Dance drugs; Dose related neurotoxicity; Polysubstance use; Harm reduction **64**, 9

EEG; Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Evoked potentials; Conduct disorder **63**, 87

Emergency; Drug use; Methadone; Maintenance; Mortality **64**, 251

Emergency medicine; Forensic science; Forensic medicine; Drug-related emergencies; Drug-related deaths **61**, 307

Emotional support; Methadone patients; Social relationships; Needle sharing; Intravenous drug use **64**, 47

Employment; Crack; Cocaine powder; Heroin; Economics; Gender; Epidemiology **64**, 191

Employment status; Outpatient treatment; Substance use diagnosis; Gender; Ethnicity; Attendance **62**, 9

Enantiomer; Methadone; Blood; Addiction; Cytochrome P-450 **61**, 47

Ephedrine; Blood pressure; Heart rate; Illicit synthesis; Pseudoephedrine; Rat **64**, 299

Epidemiological methods; Substance misuse; Cocaine; Sampling; Brazil **63**, 79

Epidemiological survey; Substance abuse; Opiate users; Maintenance treatments; Harm reduction policies **61**, 281

Epidemiologic studies; Substance-related disorders; Cannabis; Survival analysis; Natural history **64**, 123

Epidemiology; Adolescence; Alcohol; Culture; Dependence **63**, 229

Epidemiology; Aggression; Delinquent behavior; Conduct disorder; Substance-related disorders **63**, 245

Epidemiology; Alcoholism; Depressive disorder; Comorbidity **63**, 277

Epidemiology; Crack; Cocaine powder; Heroin; Economics; Employment; Gender **64**, 191

Epidemiology; *Gamma*-hydroxybutyrate; GHB, abuse potential, pharmacology; Patterns of use and abuse; Review **63**, 1

Epidemiology; HIV; Injection drug users; Risk reduction; Time-trends **61**, 315

Equilibrium; Alcohol; Caffeine; Automobile driving; Psychomotor performance **63**, 123

Ethanol; Discrimination; Self-administration; Oral **64**, 243

Ethanol; Exercise; Muscle metabolism; Fiber area; Fiber type; Capillarity; Rats **64**, 27

Ethanol; Plasma Δ^9-tetrahydrocannabinol (THC) levels; Polydrug abuse; Marihuana; Human subjects **64**, 143

Ethnicity; Outpatient treatment; Substance use diagnosis; Gender; Employment status; Attendance **62**, 9

Evoked potentials; Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Conduct disorder; EEG **63**, 87

Excitotoxicity; Alcohol dependence; Alcohol withdrawal; NMDA receptor; Primary cortical culture **61**, 155

Exercise; Ethanol; Muscle metabolism; Fiber area; Fiber type; Capillarity; Rats **64**, 27

Family history; Heroin addiction; Genetics; Treatment outcome; Methadone; Maintenance **61**, 261

Feeding; Abuse potential; Benzodiazepine; CL 284846; Dependence; Triazolam; Zaleplon **61**, 69

Feeding; Abuse potential; CL 284,846; Drug discrimination; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Feline immunodeficiency virus (FIV); Lentivirus; HIV/AIDS; Immunosuppression; Opiates; Molecular biology; Cats **62**, 125

Fenfluramine; Alcohol; Prolactin; SSRI **63**, 263

Fiber area; Ethanol; Exercise; Muscle metabolism; Fiber type; Capillarity; Rats **64**, 27

Fiber type; Ethanol; Exercise; Muscle metabolism; Fiber area; Capillarity; Rats **64**, 27

Fitness to drive; Illegal drugs; Automobile driving licence; Drug-Dependence **64**, 19

Flumazenil; Abuse potential; CL 284,846; Drug discrimination; Feeding; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Flunitrazepam; Absorption rate; Pharmacokinetics; Rate of onset of effects; Abuse liability **64**, 285

Flunitrazepam; Drug discrimination; Self-administration; Rhesus monkey; Pentobarbital-dependent rats **63**, 39

Fluoxetine; Cocaine; Depression; Dual-diagnosis; Treatment **63**, 207

Flupenthixol; Cocaine; Pharmacotherapy; Subjective effects; Cardiovascular effects; Pharmacokinetic effects **64**, 271

Follow-up; Cocaine; Assessment; Treatment **62**, 19

Follow-up; Opiate abuse; Mortality; Early predictors; Vietnam veterans **64**, 309

Forensic medicine; Forensic science; Emergency medicine; Drug-related emergencies; Drug-related deaths **61**, 307

Forensic science; Forensic medicine; Emergency medicine; Drug-related emergencies; Drug-related deaths **61**, 307

Fosinopril; Cocaine; Cardiovascular; Platelet activation; Methadone; ACE-inhibitors **61**, 35

Foster care; Injection drug users; Children; HIV; Parental drug use; Children of substance abusing parents **61**, 113

Frequency of drinking; Alcohol Use Disorders Identification Test (AUDIT); Psychometric analysis; Switzerland; Confirmatory factor analysis **64**, 151

Gambling; Substance abuse; Impulsivity **63**, 29

Gamma-amino-butyric acid; Alcoholism; Gamma-hydroxy-butyric acid; Growth hormone **61**, 217

***Gamma*-hydroxybutyrate**; GHB, abuse potential, pharmacology; Patterns of use and abuse; Epidemiology; Review **63**, 1

Gamma-hydroxy-butyric acid; Alcoholism; Gamma-amino-butyric acid; Growth hormone **61**, 217

Gay and Bisexual Men; Young; Substance Use; Prevalence; Correlates **61**, 105

GBR 12909; Cocaine; Phentermine; Progressive ratio; Self-administration; Pharmacotherapy; Abuse potential **62**, 41

Gender; Abuse; Cannabis; Cohort; Dependence; Longitudinal study; Use **64**, 347

Gender; Antisocial; Treatment outcome; Substance abuse; Outpatient **61**, 23

Gender; Crack; Cocaine powder; Heroin; Economics; Employment; Epidemiology **64**, 191

Gender differences; Drinking; Response conflict; Cognitions; Gender stereotypes **61**, 129

Gender; Opioid; Morphine; Sex; Behavior; Human **63**, 23

Gender; κ-Opioids; Analgesia; Locomotor activity **63**, 215

Gender; Outpatient treatment; Substance use diagnosis; Ethnicity; Employment status; Attendance **62**, 9

Gender stereotypes; Drinking; Gender differences; Response conflict; Cognitions **61**, 129

Gene expression; Drug abuse; Genes; CART **62**, 157

Gene induction; Mu-receptor; T-lymphocyte; Morphine; Mitogen **62**, 131

Genes; Drug abuse; Gene expression; CART **62**, 157

Genetic; Alcohol dependence; Illicit drug dependence; Posttraumatic stress disorder; Twins; Veterans **61**, 95

Genetic and environmental influences; Marijuana use; Sensation seeking; Risk taking; Add health study **62**, 57

Genetics; Heroin addiction; Family history; Treatment outcome; Methadone; Maintenance **61**, 261

GHB, abuse potential, pharmacology; *Gamma*-hydroxybutyrate; Patterns of use and abuse; Epidemiology; Review **63**, 1

Growth hormone; Alcoholism; Gamma-amino-butyric acid; Gamma-hydroxy-butyric acid **61**, 217

Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Subjective effects; Reliability; Convergent analysis **62**, 215

Hallucinogens; β-carbolines; Harmine; Harmaline; Imidazoline binding sites; SAR **64**, 203

Harmaline; β-carbolines; Harmine; Hallucinogens; Imidazoline binding sites; SAR **64**, 203

Harmine; β-carbolines; Harmaline; Hallucinogens; Imidazoline binding sites; SAR **64**, 203

Harm reduction; Ecstasy; Dance drugs; Dose related neurotoxicity; Polysubstance use **64**, 9

Harm reduction policies; Substance abuse; Opiate users; Maintenance treatments; Epidemiological survey **61**, 281

Health; Injection sites; Drug users; Sydney **62**, 77

Health service utilization; HIV/AIDS; Case management; Drug treatment; Injection drug users **64**, 55

Heart rate; Blood pressure; Ephedrine; Illicit synthesis; Pseudoephedrine; Rat **64**, 299

Heavy drinkers; Alcohol; Negative reinforcement **64**, 337

Helplines; Substance-related disorders; Therapy **62**, 191

Hepatitis B; Hepatitis C; Methadone; Injection drug users; Sexually transmitted disease **61**, 211

Hepatitis C; Hepatitis B; Methadone; Injection drug users; Sexually transmitted disease **61**, 211

Heroin addiction; Family history; Genetics; Treatment outcome; Methadone; Maintenance **61**, 261

Heroin; Age; Sequence of substance use; Drug users; Opiates **64**, 105

Heroin; Crack; Cocaine powder; Economics; Employment; Gender; Epidemiology **64**, 191

Heroin; Dependence; Administration route; SDS scale **63**, 169

Heroin dependence; Amantadine; Cocaine use disorder; Detoxification; Methadone; Opioid withdrawal **63**, 187

Heroin dependence; Buprenorphine; Human; Opioid withdrawal; Treatment **64**, 111

Heroin dependence; Novelty seeking; Anti-social personality disorder; Buprenorphine; Poly-drug use; Contingency management; Treatment outcome **61**, 287

Heroin; Opiates; Injecting drug use; Methadone; Cost-of-illness; Economics; Policy **61**, 195

Heroin; Opioid addiction; Detoxification; Methadone; Codeine **64**, 173

Heroin; Toxicology; Morphine; Death; Demographics **61**, 123

HIV/AIDS; Health service utilization; Case management; Drug treatment; Injection drug users **64**, 55

HIV/AIDS; Lentivirus; Feline immunodeficiency virus (FIV); Immunosuppression; Opiates; Molecular biology; Cats **62**, 125

HIV/AIDS; U50,488; κ-Opioid receptors; Immunobiology; Macrophages; RANTES **62**, 149

HIV; Drug users; Sexual risk behaviors; Sex partners **64**, 97

HIV; Injection drug users; Children; Parental drug use; Children of substance abusing parents; Foster care **61**, 113

HIV; Injection drug users; Risk reduction; Epidemiology; Time-trends **61**, 315

HIV; Methamphetamine; Cocaine; Stimulant; Treatment **62**, 91

HIV prevention; Injection drug use; Substance abuse; Syringe exchange programs; Treatment **62**, 225

HIV review; Opiate abuse; Immune function; Immunobiology; Molecular biology **62**, 111

HMO alcohol costs; Alcohol use; Drinking patterns and costs; U-shaped drinking curve **64**, 181

Hormonal effects; Brain imaging; Magnetic resonance imaging; Cocaine dependence **62**, 49

Human; Buprenorphine; Heroin dependence; Opioid withdrawal; Treatment **64**, 111

Human immunodeficiency virus; Indinavir; Naloxone; Naltrexone; Zidovudine **64**, 257

Human; Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Abuse liability; Inhalants **64**, 85

Human; Opioid; Morphine; Sex; Gender; Behavior **63**, 23

Humans; Alprazolam; Caffeine; Drug discrimination; Novel-response procedure; Triazolam; Zolpidem **61**, 249

Human subjects; Ethanol; Plasma Δ^9-tetrahydrocannabinol (THC) levels; Polydrug abuse; Marihuana **64**, 143

Hyperalgesia; Pain; Methadone; Buprenorphine; Cold pressor **63**, 139

Hypothermia; Marijuana smoking; Cannabinoid; Δ^9-THC; SR 141716A; Antinociception; Analgesia; Catalepsy **63**, 107

ICD-10; DSM-IV; Cannabis dependence; Australian adults **63**, 147

Illegal drugs; Automobile driving licence; Fitness to drive; Drug-Dependence **64**, 19

Illicit drug dependence; Alcohol dependence; Genetic; Posttraumatic stress disorder; Twins; Veterans **61**, 95

Illicit drugs; Medical students; Pre-registration house officers; Alcohol; Stress **64**, 265

Illicit synthesis; Blood pressure; Ephedrine; Heart rate; Pseudoephedrine; Rat **64**, 299

Imidazoline binding sites; β-carbolines; Harmine; Harmaline; Hallucinogens; SAR **64**, 203

Immediate versus delayed retrospective assessment; Hallucinogen Rating Scale (HRS); Subjective effects; Reliability; Convergent analysis **62**, 215

Immune function; Opiate abuse; Immunobiology; Molecular biology; HIV review **62**, 111

Immunobiology; HIV/AIDS; U50,488; κ-Opioid receptors; Macrophages; RANTES **62**, 149

Immunobiology; Opiate abuse; Immune function; Molecular biology; HIV review **62**, 111

Immunobiology; Opiates; Nicotinic receptor; Lympbocytes; Autonomic nervous system **62**, 141

Immunosuppression; Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Opiates; Molecular biology; Cats **62**, 125

Impulsivity; Substance abuse; Gambling **63**, 29

Incentives; Contingency management; Technology transfer; Performance feedback; Performance management; Drug treatment counselors **63**, 179

Indinavir; Human immunodeficiency virus; Naloxone; Naltrexone; Zidovudine **64**, 257

Inhalants; Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Abuse liability; Human **64**, 85

Inhalants; Volatile solvents; Nosology; Diagnostic concordance **61**, 223

Injecting drug use; Heroin; Opiates; Methadone; Cost-of-illness; Economics; Policy **61**, 195

Injection drug users; Children; HIV; Parental drug use; Children of substance abusing parents; Foster care **61**, 113

Injection drug users; Hepatitis C; Hepatitis B; Methadone; Sexually transmitted disease **61**, 211

Injection drug users; HIV/AIDS; Health service utilization; Case management; Drug treatment **64**, 55

Injection drug users; HIV; Risk reduction; Epidemiology; Time-trends **61**, 315

Injection drug use; Stimulants; Substance abuse treatment; Psychological symptoms **64**, 165

Injection drug use; Substance abuse; Syringe exchange programs; HIV prevention; Treatment **62**, 225

Injection sites; Drug users; Sydney; Health **62**, 77

Inpatient detoxification; Substance dependence; Contingency management; Outpatient aftercare; Treatment compliance **61**, 137

Insomnia; Adolescent; Sleep problems; Alcohol; Tobacco; Drug abuse **64**, 1

Intravenous drug use; Methadone patients; Social relationships; Needle sharing; Emotional support **64**, 47

Intravenous drug use; Utilization; Complications; Services research **64**, 117

Laboratory stress; Social phobia; Co-morbidity; Alcohol use; Alcohol challenge **64**, 219

Lack of interest; Academic achievement; Adolescence; Cannabis; Coitus **62**, 175

Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Opiates; Molecular biology; Cats **62**, 125

Liability; Puberty; Adolescence; Affective, cognitive, and behavioral dysregulation; Neuroadaptation; Substance use disorder **61**, 3

Locomotor activity; Morphine; Sensitization; Rats **62**, 83

Locomotor activity; κ-Opioids; Analgesia; Gender **63**, 215

Longitudinal; Cocaine; Marijuana; Methodology; Survey **62**, 239

Longitudinal study; Abuse; Cannabis; Cohort; Dependence; Gender; Use **64**, 347

Lympbocytes; Immunobiology; Opiates; Nicotinic receptor; Autonomic nervous system **62**, 141

Macrophages; HIV/AIDS; U50,488; κ-Opioid receptors; Immunobiology; RANTES **62**, 149

Magnetic resonance imaging; Brain imaging; Hormonal effects; Cocaine dependence **62**, 49

Maintenance; Drug use; Methadone; Emergency; Mortality **64**, 251

Maintenance; Heroin addiction; Family history; Genetics; Treatment outcome; Methadone **61**, 261

Maintenance treatments; Substance abuse; Opiate users; Epidemiological survey; Harm reduction policies **61**, 281

Major depression; Alcohol dependence; Panic disorder; Cultural factors; Dysthymia **63**, 117

Malnutrition; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition **63**, 199

Marihuana; Ethanol; Plasma Δ^9-tetrahydrocannabinol (THC) levels; Polydrug abuse; Human subjects **64**, 143

Marijuana; Cocaine; Longitudinal; Methodology; Survey **62**, 239

Marijuana smoking; Cannabinoid; Δ^9-THC; SR 141716A; Antinociception; Analgesia; Catalepsy; Hypothermia **63**, 107

Marijuana use; Genetic and environmental influences; Sensation seeking; Risk taking; Add health study **62**, 57

Marijuana use; Sensation seeking; Adolescents; Cigarette use; Disinhibition **62**, 195

Medical ethics; Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Patient-therapist relationship; Candor **61**, 191

Medical students; Pre-registration house officers; Alcohol; Illicit drugs; Stress **64**, 265

Mesolimbic pathway; Tyrosine hydroxylase; Catecholamines; Cocaine; Tropanes **61**, 15

Metabolism; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

Methadone; Amantadine; Cocaine use disorder; Detoxification; Heroin dependence; Opioid withdrawal **63**, 187

Methadone; Cocaine; Cardiovascular; Platelet activation; ACE-inhibitors; Fosinopril **61**, 35

Methadone; Drug use; Maintenance; Emergency; Mortality **64**, 251

Methadone; Enantiomer; Blood; Addiction; Cytochrome P-450 **61**, 47

Methadone; Hepatitis C; Hepatitis B; Injection drug users; Sexually transmitted disease **61**, 211

Methadone; Heroin addiction; Family history; Genetics; Treatment outcome; Maintenance **61**, 261

Methadone; Heroin; Opiates; Injecting drug use; Cost-of-illness; Economics; Policy **61**, 195

Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Patient-therapist relationship; Candor; Medical ethics **61**, 191

Methadone maintenance; Buprenorphine tablet; Opioids; Controlled trial **62**, 97

Methadone maintenance; Opiate addiction; Buprenorphine; Cost-effectiveness **63**, 253

Methadone maintenance; Pregnancy; Behavioral incentives; Contingency management; Perinatal addictions **61**, 297

Methadone maintenance treatment; Methadone reduction treatment **62**, 255

Methadone; Opioid addiction; Detoxification; Heroin; Codeine **64**, 173

Methadone; Pain; Buprenorphine; Cold pressor; Hyperalgesia **63**, 139

Methadone patients; Social relationships; Needle sharing; Intravenous drug use; Emotional support **64**, 47

Methadone reduction treatment; Methadone maintenance treatment **62**, 255

Methadone; Take-homes; Contingency management; Opiates; Cocaine **62**, 69

Methadone; Treatment outcome; Personality disorders; Psychiatric diagnosis; Comorbidity **61**, 271

Methamphetamine; Cocaine; Stimulant; Treatment; HIV **62**, 91

Methamphetamine; Craving; Relapse; Treatment **63**, 269

Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; Noradrenergic hyperactivity; 3-Methoxytyramine; Distressing situations **64**, 133

Methodology; Cocaine; Longitudinal; Marijuana; Survey **62**, 239

3-Methoxytyramine; Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; Noradrenergic hyperactivity; Distressing situations **64**, 133

Mitogen; Mu-receptor; T-lymphocyte; Morphine; Gene induction **62**, 131

Molecular biology; Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Opiates; Cats **62**, 125

Molecular biology; Opiate abuse; Immune function; Immunobiology; HIV review **62**, 111

Morphine; Mu-receptor; T-lymphocyte; Mitogen; Gene induction **62**, 131

Morphine; Opioid; Sex; Gender; Behavior; Human **63**, 23

Morphine; Sensitization; Locomotor activity; Rats **62**, 83

Morphine; Toxicology; Heroin; Death; Demographics **61**, 123

Mortality; Drug use; Methadone; Maintenance; Emergency **64**, 251

Mortality; Opiate abuse; Early predictors; Vietnam veterans; Follow-up **64**, 309

Mu-receptor; T-lymphocyte; Morphine; Mitogen; Gene induction **62**, 131

Muscle metabolism; Ethanol; Exercise; Fiber area; Fiber type; Capillarity; Rats **64**, 27

Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

Myosin; Myopathy; Biochemical mechanisms; Protein synthesis; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

Naloxone; Buprenorphine; Opiate withdrawal; Sublingual; Pharmacokinetics **61**, 85

Naloxone; Human immunodeficiency virus; Indinavir; Naltrexone; Zidovudine **64**, 257

Naltrexone; Anesthesia; ACTH; Cortisol; Craving; Withdrawal **61**, 163

Naltrexone; Human immunodeficiency virus; Indinavir; Naloxone; Zidovudine **64**, 257

Natural history; Substance-related disorders; Cannabis; Epidemiologic studies; Survival analysis **64**, 123

Needle sharing; Methadone patients; Social relationships; Intravenous drug use; Emotional support **64**, 47

Negative reinforcement; Alcohol; Heavy drinkers **64**, 337

Neonatal abstinence syndrome; Pregnancy; Buprenorphine; Opioid dependence; Treatment; Perinatal addiction **63**, 97

Neuroadaptation; Liability; Puberty; Adolescence; Affective, cognitive, and behavioral dysregulation; Substance use disorder **61**, 3

Nicotine replacement; Smoking cessation; Self-help; Behavioral treatment; Smoking **64**, 35

Nicotinic receptor; Immunobiology; Opiates; Lympbocytes; Autonomic nervous system **62**, 141

Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Abuse liability; Inhalants; Human **64**, 85

NMDA receptor; Alcohol dependence; Alcohol withdrawal; Excitotoxicity; Primary cortical culture **61**, 155

Noradrenergic hyperactivity; Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; 3-Methoxytyramine; Distressing situations **64**, 133

Nosology; Inhalants; Volatile solvents; Diagnostic concordance **61**, 223

Nosology; Substance abuse and dependence; Diagnosis; CIDI-SAM; Physiological dependence **61**, 237

Novel-response procedure; Alprazolam; Caffeine; Drug discrimination; Humans; Triazolam; Zolpidem **61**, 249

Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Poly-drug use; Contingency management; Treatment outcome **61**, 287

Nutrition; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Malnutrition **63**, 199

Opiate abuse; Immune function; Immunobiology; Molecular biology; HIV review **62**, 111

Opiate abuse; Mortality; Early predictors; Vietnam veterans; Follow-up **64**, 309

Opiate addiction; Methadone maintenance; Buprenorphine; Cost-effectiveness **63**, 253

Opiates; Age; Sequence of substance use; Drug users; Heroin **64**, 105

Opiates; Heroin; Injecting drug use; Methadone; Cost-of-illness; Economics; Policy **61**, 195

Opiates; Immunobiology; Nicotinic receptor; Lympbocytes; Autonomic nervous system **62**, 141

Opiates; Lentivirus; Feline immunodeficiency virus (FiV); HIV/AIDS; Immunosuppression; Molecular biology; Cats **62**, 125

Opiates; Methadone; Take-homes; Contingency management; Cocaine **62**, 69

Opiate users; Substance abuse; Maintenance treatments; Epidemiological survey; Harm reduction policies **61**, 281

Opiate withdrawal; Buprenorphine; Naloxone; Sublingual; Pharmacokinetics **61**, 85

Opioid addiction; Detoxification; Heroin; Methadone; Codeine **64**, 173

Opioid dependence; Pregnancy; Buprenorphine; Treatment; Neonatal abstinence syndrome; Perinatal addiction **63**, 97

Opioid; Morphine; Sex; Gender; Behavior; Human **63**, 23

κ-Opioid receptors; HIV/AIDS; U50,488; Immunobiology; Macrophages; RANTES **62**, 149

κ-Opioids; Analgesia; Locomotor activity; Gender **63**, 215

Opioids; Buprenorphine tablet; Methadone maintenance; Controlled trial **62**, 97

Opioids; Tolerance; Rhesus monkeys; Self-administration **62**, 181

Opioid withdrawal; Amantadine; Cocaine use disorder; Detoxification; Heroin dependence; Methadone **63**, 187

Opioid withdrawal; Buprenorphine; Heroin dependence; Human; Treatment **64**, 111

Oral; Ethanol; Discrimination; Self-administration **64**, 243

Outpatient aftercare; Substance dependence; Contingency management; Inpatient detoxification; Treatment compliance **61**, 137

Outpatient; Antisocial; Treatment outcome; Substance abuse; Gender **61**, 23

Outpatient; Cocaine dependence; Treatment intensity; Psychosocial treatment; Day hospital; Services **61**, 145

Outpatient treatment; Substance use diagnosis; Gender; Ethnicity; Employment status; Attendance **62**, 9

Pain; Methadone; Buprenorphine; Cold pressor; Hyperalgesia **63**, 139

Panadiplon (U–78875, PNU-78875); Benzodiazepine; Barbiturates; Pentobarbital; Drug discrimination; Abuse potential **61**, 229

Panic disorder; Alcohol dependence; Cultural factors; Major depression; Dysthymia **63**, 117

Parental drug use; Injection drug users; Children; HIV; Children of substance abusing parents; Foster care **61**, 113

Patient-therapist relationship; Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Candor; Medical ethics **61**, 191

Patterns of use and abuse; *Gamma*-hydroxybutyrate; GHB, abuse potential, pharmacology; Epidemiology; Review **63**, 1

Pentobarbital; Benzodiazepine; Barbiturates; Drug discrimination; Panadiplon (U–78875, PNU-78875); Abuse potential **61**, 229

Pentobarbital-dependent rats; Flunitrazepam; Drug discrimination; Self-administration; Rhesus monkey **63**, 39

Performance feedback; Contingency management; Technology transfer; Incentives; Performance management; Drug treatment counselors **63**, 179

Performance management; Contingency management; Technology transfer; Performance feedback; Incentives; Drug treatment counselors **63**, 179

Perinatal addiction; Pregnancy; Buprenorphine; Opioid dependence; Treatment; Neonatal abstinence syndrome **63**, 97

Perinatal addictions; Pregnancy; Behavioral incentives; Contingency management; Methadone maintenance **61**, 297

Personality disorders; Methadone; Treatment outcome; Psychiatric diagnosis; Comorbidity **61**, 271

Pharmacokinetic effects; Cocaine; Pharmacotherapy; Flupenthixol; Subjective effects; Cardiovascular effects **64**, 271

Pharmacokinetics; Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Pharmacokinetics; Buprenorphine; Naloxone; Opiate withdrawal; Sublingual **61**, 85

Pharmacokinetics; Flunitrazepam; Absorption rate; Rate of onset of effects; Abuse liability **64**, 285

Pharmacotherapy; Buprenorphine; Buprenorphine-naloxone; Dosing regimen; Abuse **61**, 173

Pharmacotherapy; Cocaine; Bupropion **63**, 155

Pharmacotherapy; Cocaine; Flupenthixol; Subjective effects; Cardiovascular effects; Pharmacokinetic effects **64**, 271

Pharmacotherapy; Cocaine; GBR 12909; Phentermine; Progressive ratio; Self-administration; Abuse potential **62**, 41

Pharmacotherapy; Cocaine withdrawal; Propranolol; Double-blind; Beta-blocker **63**, 69

Pharmacotherapy; Ritanserin; Cocaine dependence; Serotonin antagonist; Treament **61**, 183

Phentermine; Cocaine; GBR 12909; Progressive ratio; Self-administration; Pharmacotherapy; Abuse potential **62**, 41

Physiological dependence; Substance abuse and dependence; Diagnosis; CIDI-SAM; Nosology **61**, 237

Physiological response; Depressive symptoms; Depression; Cocaine; Subjective response **63**, 131

Plasma Δ^9-tetrahydrocannabinol (THC) levels; Ethanol; Polydrug abuse; Marihuana; Human subjects **64**, 143

Platelet activation; Cocaine; Cardiovascular; Methadone; ACE-inhibitors; Fosinopril **61**, 35

Policy; Heroin; Opiates; Injecting drug use; Methadone; Cost-of-illness; Economics **61**, 195

Polydrug abuse; Alcohol abuse; Behavioral economics **62**, 31

Polydrug abuse; Ethanol; Plasma Δ^9-tetrahydrocannabinol (THC) levels; Marihuana; Human subjects **64**, 143

Poly-drug use; Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Contingency management; Treatment outcome **61**, 287

Polysubstance use; Ecstasy; Dance drugs; Dose related neurotoxicity; Harm reduction **64**, 9

Population; Cannabis; Comorbidity; Drug use; Alcohol; Tobacco **64**, 319

Positive reinforcement; D2 agonists; Psychomotor stimulant; Cocaine; Self-administration; Rhesus monkey **64**, 209

Posttraumatic stress disorder; Alcohol dependence; Genetic; Illicit drug dependence; Twins; Veterans **61**, 95

Pregnancy; Behavioral incentives; Contingency management; Perinatal addictions; Methadone maintenance **61**, 297

Pregnancy; Buprenorphine; Opioid dependence; Treatment; Neonatal abstinence syndrome; Perinatal addiction **63**, 97

Pre-registration house officers; Medical students; Alcohol; Illicit drugs; Stress **64**, 265

Prevalence; Ecstasy consumption; Social class; 18 year-olds **64**, 329

Prevalence; Gay and Bisexual Men; Young; Substance Use; Correlates **61**, 105

Primary cortical culture; Alcohol dependence; Alcohol withdrawal; NMDA receptor; Excitotoxicity **61**, 155

Progressive ratio; Cocaine; GBR 12909; Phentermine; Self-administration; Pharmacotherapy; Abuse potential **62**, 41

Prolactin; Alcohol; Fenfluramine; SSRI **63**, 263

Prolactin; Cocaine withdrawal; Cortisol; Serotonin; Dopamine **64**, 63

Propranolol; Cocaine withdrawal; Pharmacotherapy; Double-blind; Beta-blocker **63**, 69

Protein synthesis; Myopathy; Biochemical mechanisms; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

Proteolysis; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Nutrition; Malnutrition **63**, 199

Pseudoephedrine; Blood pressure; Ephedrine; Heart rate; Illicit synthesis; Rat **64**, 299

Psychiatric diagnosis; Methadone; Treatment outcome; Personality disorders; Comorbidity **61**, 271

Psychological symptoms; Injection drug use; Stimulants; Substance abuse treatment **64**, 165

Psychometric analysis; Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Switzerland; Confirmatory factor analysis **64**, 151

Psychomotor performance; Alcohol; Caffeine; Automobile driving; Equilibrium **63**, 123

Psychomotor stimulant; D2 agonists; Cocaine; Self-administration; Positive reinforcement; Rhesus monkey **64**, 209

Psychosocial treatment; Cocaine dependence; Treatment intensity; Outpatient; Day hospital; Services **61**, 145

Puberty; Liability; Adolescence; Affective, cognitive, and behavioral dysregulation; Neuroadaptation; Substance use disorder **61**, 3

RANTES; HIV/AIDS; U50,488; κ-Opioid receptors; Immunobiology; Macrophages **62**, 149

Rat; Blood pressure; Ephedrine; Heart rate; Illicit synthesis; Pseudoephedrine **64**, 299

Rate of onset of effects; Flunitrazepam; Absorption rate; Pharmacokinetics; Abuse liability **64**, 285

Rats; Ethanol; Exercise; Muscle metabolism; Fiber area; Fiber type; Capillarity **64**, 27

Rats; Morphine; Sensitization; Locomotor activity **62**, 83

Reinforcing effects; Nitrous oxide; Subjective effects; Choice; Abuse liability; Inhalants; Human **64**, 85

Relapse; Craving; Methamphetamine; Treatment **63**, 269

Relapse prediction; Dopamine receptor responsivity; Alcohol detoxification **64**, 363

Reliability; Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Subjective effects; Convergent analysis **62**, 215

Respiratory disease; Cannabis; Accidents; Dependence; Adverse effects **62**, 163

Response conflict; Drinking; Gender differences; Cognitions; Gender stereotypes **61**, 129

Review; *Gamma*-hydroxybutyrate; GHB, abuse potential, pharmacology; Patterns of use and abuse; Epidemiology **63**, 1

Rhesus monkey; D2 agonists; Psychomotor stimulant; Cocaine; Self-administration; Positive reinforcement **64**, 209

Rhesus monkey; Flunitrazepam; Drug discrimination; Self-administration; Pentobarbital-dependent rats **63**, 39

Rhesus monkeys; Tolerance; Opioids; Self-administration **62**, 181

Risk reduction; HIV; Injection drug users; Epidemiology; Time-trends **61**, 315

Risk taking; Genetic and environmental influences; Marijuana use; Sensation seeking; Add health study **62**, 57

Ritanserin; Pharmacotherapy; Cocaine dependence; Serotonin antagonist; Treament **61**, 183

RNA; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; Proteolysis; Nutrition; Malnutrition **63**, 199

Sampling; Substance misuse; Cocaine; Epidemiological methods; Brazil **63**, 79

SAR; β-carbolines; Harmine; Harmaline; Hallucinogens; Imidazoline binding sites **64**, 203

SDS scale; Heroin; Dependence; Administration route **63**, 169

Self-administration; Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Triazolam; Zaleplon; Zolpidem **61**, 55

Self-administration; Cocaine; GBR 12909; Phentermine; Progressive ratio; Pharmacotherapy; Abuse potential **62**, 41

Self-administration; D2 agonists; Psychomotor stimulant; Cocaine; Positive reinforcement; Rhesus monkey **64**, 209

Self-administration; Ethanol; Discrimination; Oral **64**, 243

Self-administration; Flunitrazepam; Drug discrimination; Rhesus monkey; Pentobarbital-dependent rats **63**, 39

Self-administration; Tolerance; Opioids; Rhesus monkeys **62**, 181

Self-help; Smoking cessation; Nicotine replacement; Behavioral treatment; Smoking **64**, 35

Sensation seeking; Adolescents; Cigarette use; Disinhibition; Marijuana use **62**, 195

Sensation seeking; Genetic and environmental influences; Marijuana use; Risk taking; Add health study **62**, 57

Sensitization; Morphine; Locomotor activity; Rats **62**, 83

Sequence of substance use; Age; Drug users; Opiates; Heroin **64**, 105

Serotonin antagonist; Pharmacotherapy; Ritanserin; Cocaine dependence; Treament **61**, 183

Serotonin; Cocaine withdrawal; Prolactin; Cortisol; Dopamine **64**, 63

Services; Cocaine dependence; Treatment intensity; Psychosocial treatment; Outpatient; Day hospital **61**, 145

Services research; Intravenous drug use; Utilization; Complications **64**, 117

Sex; Opioid; Morphine; Gender; Behavior; Human **63**, 23

Sex partners; Drug users; Sexual risk behaviors; HIV **64**, 97

Sexually transmitted disease; Hepatitis C; Hepatitis B; Methadone; Injection drug users **61**, 211

Sexual risk behaviors; Drug users; Sex partners; HIV **64**, 97

Sleep problems; Adolescent; Insomnia; Alcohol; Tobacco; Drug abuse **64**, 1

Smoking cessation; Self-help; Nicotine replacement; Behavioral treatment; Smoking **64**, 35

Smoking; Smoking cessation; Self-help; Nicotine replacement; Behavioral treatment **64**, 35

Social class; Ecstasy consumption; Prevalence; 18 year-olds **64**, 329

Social phobia; Co-morbidity; Alcohol use; Alcohol challenge; Laboratory stress **64**, 219

Social problems; Drinking and driving; Alcohol abuse; Alcohol consumption; Traffic accidents **62**, 231

Social relationships; Methadone patients; Needle sharing; Intravenous drug use; Emotional support **64**, 47

SR 141716A; Marijuana smoking; Cannabinoid; Δ^9-THC; Antinociception; Analgesia; Catalepsy; Hypothermia **63**, 107

SSRI; Alcohol; Prolactin; Fenfluramine **63**, 263

Stimulant; Methamphetamine; Cocaine; Treatment; HIV **62**, 91

Stimulants; Injection drug use; Substance abuse treatment; Psychological symptoms **64**, 165

Stress; Medical students; Pre-registration house officers; Alcohol; Illicit drugs **64**, 265

Subjective effects; Cocaine; Pharmacotherapy; Flupenthixol; Cardiovascular effects; Pharmacokinetic effects **64**, 271

Subjective effects; Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Reliability; Convergent analysis **62**, 215

Subjective effects; Nitrous oxide; Choice; Reinforcing effects; Abuse liability; Inhalants; Human **64**, 85

Subjective response; Depressive symptoms; Depression; Cocaine; Physiological response **63**, 131

Sublingual; Buprenorphine; Naloxone; Opiate withdrawal; Pharmacokinetics **61**, 85

Subsequent flashbacks; Methamphetamine psychosis; Susceptibility; Noradrenergic hyperactivity; 3-Methoxytyramine; Distressing situations **64**, 133

Substance abuse and dependence; Diagnosis; CIDI-SAM; Physiological dependence; Nosology **61**, 237

Substance abuse; Antisocial; Treatment outcome; Gender; Outpatient **61**, 23

Substance abuse; Gambling; Impulsivity **63**, 29

Substance abuse; Injection drug use; Syringe exchange programs; HIV prevention; Treatment **62**, 225

Substance abuse; Opiate users; Maintenance treatments; Epidemiological survey; Harm reduction policies **61**, 281

Substance abuse treatment; Injection drug use; Stimulants; Psychological symptoms **64**, 165

Substance dependence; Contingency management; Inpatient detoxification; Outpatient aftercare; Treatment compliance **61**, 137

Substance misuse; Cocaine; Epidemiological methods; Sampling; Brazil **63**, 79

Substance-related disorders; Cannabis; Epidemiologic studies; Survival analysis; Natural history **64**, 123

Substance-related disorders; Epidemiology; Aggression; Delinquent behavior; Conduct disorder **63**, 245

Substance-related disorders; Helplines; Therapy **62**, 191

Substance use diagnosis; Outpatient treatment; Gender; Ethnicity; Employment status; Attendance **62**, 9

Substance use disorder; Liability; Puberty; Adolescence; Affective, cognitive, and behavioral dysregulation; Neuroadaptation **61**, 3

Substance Use; Gay and Bisexual Men; Young; Prevalence; Correlates **61**, 105

Survey; Cocaine; Longitudinal; Marijuana; Methodology **62**, 239

Survival analysis; Substance-related disorders; Cannabis; Epidemiologic studies; Natural history **64**, 123

Susceptibility; Methamphetamine psychosis; Subsequent flashbacks; Noradrenergic hyperactivity; 3-Methoxytyramine; Distressing situations **64**, 133

Switzerland; Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Psychometric analysis; Confirmatory factor analysis **64**, 151

Sydney; Injection sites; Drug users; Health **62**, 77

Syringe exchange programs; Injection drug use; Substance abuse; HIV prevention; Treatment **62**, 225

Take-homes; Methadone; Contingency management; Opiates; Cocaine **62**, 69

Technology transfer; Contingency management; Performance feedback; Incentives; Performance management; Drug treatment counselors **63**, 179

Δ^9-THC; Marijuana smoking; Cannabinoid; SR 141716A; Antinociception; Analgesia; Catalepsy; Hypothermia **63**, 107

Therapy; Helplines; Substance-related disorders **62**, 191

Time perception; Antisocial personality disorder; Cocaine dependence; Contingent negative variation; Evoked potentials; Conduct disorder; EEG **63**, 87

Time-trends; HIV; Injection drug users; Risk reduction; Epidemiology **61**, 315

T-lymphocyte; Mu-receptor; Morphine; Mitogen; Gene induction **62**, 131

Tobacco; Adolescent; Sleep problems; Insomnia; Alcohol; Drug abuse **64**, 1

Tobacco; Cannabis; Comorbidity; Drug use; Population; Alcohol **64**, 319

Tolerance; Opioids; Rhesus monkeys; Self-administration **62**, 181

Toxicology; Heroin; Morphine; Death; Demographics **61**, 123

Traffic accidents; Drinking and driving; Alcohol abuse; Alcohol consumption; Social problems **62**, 231

Treament; Pharmacotherapy; Ritanserin; Cocaine dependence; Serotonin antagonist **61**, 183

Treatment; Buprenorphine; Heroin dependence; Human; Opioid withdrawal **64**, 111

Treatment; Cocaine; Assessment; Follow-up **62**, 19

Treatment compliance; Substance dependence; Contingency management; Inpatient detoxification; Outpatient aftercare **61**, 137

Treatment; Craving; Methamphetamine; Relapse **63**, 269

Treatment; Fluoxetine; Cocaine; Depression; Dual-diagnosis **63**, 207

Treatment; Injection drug use; Substance abuse; Syringe exchange programs; HIV prevention **62**, 225

Treatment intensity; Cocaine dependence; Psychosocial treatment; Outpatient; Day hospital; Services **61**, 145

Treatment; Methamphetamine; Cocaine; Stimulant; HIV **62**, 91

Treatment outcome; Antisocial; Substance abuse; Gender; Outpatient **61**, 23

Treatment outcome; Cocaine dependence; Cocaine use; Urine test **62**, 1

Treatment outcome; Heroin addiction; Family history; Genetics; Methadone; Maintenance **61**, 261

Treatment outcome; Methadone; Personality disorders; Psychiatric diagnosis; Comorbidity **61**, 271

Treatment outcome; Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Poly-drug use; Contingency management **61**, 287

Treatment; Pregnancy; Buprenorphine; Opioid dependence; Neonatal abstinence syndrome; Perinatal addiction **63**, 97